Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: Definitive results of phase III randomized trial (SAKK 23/83) comparing tamoxifen with observation

Annals of Oncology

Volumn 14, Issue 8, 2003, Pages 1215-1221

  Waeber, M ^a   Castiglione Gertsch, M ^b   Dietrich, D ^b   Thurlimann B ^c   Goldhirsch, A ^b   Brunner, K W ^a   Borner, Markus M ^a   Senn, H J ^c   Cavalli, F ^d   Varini, M ^d   Harder, F ^e   Obrecht, J P ^e   Leyvraz, S ^f   Alberto, P ^g   Metzger, U ^h  

^a UNIVERSITY OF BERN   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d OSPEDALE SAN GIOVANNI   (Switzerland)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Breast cancer; Locoregional recurrence; Randomized phase III study; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RESEARCH; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXCISION; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MASTECTOMY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA IN SITU; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OBSERVATION; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0042009737     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg347     Document Type: Article

References (25)

1. Recht A, Come S, Troyan S, Sadowsky N. Management of recurrent breast cancer. Dis Breast 2000; 1: 731-747.
2. Schmoor C, Sauerbrei W, Bastert G, Schumacher M. Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. J Clin Oncol 2000; 18: 1696-1708.
3. Aberizk WJ, Silver B, Henderson IC et al. The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer 1986; 58: 1214-1218.
4. Borner M, Bacchi M, Goldhirsch A et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol 1994; 12: 2071-2077.
5. Borner MM, Bacchi M, Castiglione M. Possible deleterious effect of tamoxifen in premenopausal women with locoregional recurrence of breast cancer. Eur J Cancer 1996; 32A: 2173-2176.
6. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
7. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
8. Cox DR, McCullagh P. Some aspects of analysis of covariance. Biometrics 1982; 38: 541-561.
9. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985; 41: 361-372.
10. Prentice RL, Kalbfleisch JD, Peterson AV Jr et al. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541-554.
11. Gray RJ. A class of K-sample tests for comparing cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
12. Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 1991; 9: 1283-1297.
13. Aebi S, Gelber S, Castiglione-Gertsch M et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000; 355: 1869-1874.
14. Bonnier P, Romain S, Charpin C et al. Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer 1995; 62: 138-144.
15. Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev 2001; 27: 137-142.
16. Kamby C, Sengelov L. Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. A prospective study with more than 10 years of follow up. Breast Cancer Res Treat 1997; 45: 181-192.
17. Hsi RA, Antell A, Schultz DJ, Solin LJ. Radiation therapy for chest wall recurrence of breast cancer after mastectomy in a favorable subgroup of patients. Int J Radiat Oncol Biol Phys 1998; 42: 495-499.
18. Willner J, Kiricuta IC, Kolbl O. Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis. Int J Radiat Oncol Biol Phys 1997; 37: 853-863.
19. Schwaibold F, Fowble BL, Solin LJ et al. The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys 1991; 21: 299-310.
20. Halverson KJ, Perez CA, Kuske RR et al. Locoregional recurrence of breast cancer: a retrospective comparison of irradiation alone versus irradiation and systemic therapy. Am J Clin Oncol 1992; 15: 93-101.
21. Fortin A, Larochelle M, Laverdiere J et al. Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol 1999; 17: 101-109.
22. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758-3767.
23. Bonneterre J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18: 3748-3757.
24. Buzdar A, Douma J, Davidson N et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 19: 3357-3366.
25. Dombernowsky P, Smith I, Falkson G et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453-461.